As sales soared industry-wide in Q3, Pfizer moved into top spot
1 day ago · The performance took even Pfizer by surprise as it boosted its annual revenue projection by $1.5 billion on both ends to a new range of $61 billion to $64 billion.
FDA Approves BridgeBio Pharma's Drug For Rare Heart Disease, …
1 day ago · On Friday, the FDA approved BridgeBio Pharma, Inc.’s (NASDAQ:BBIO) Attruby (acoramidis), an orally-administered near-complete (≥90%) stabilizer of Transthyretin (TTR) for adults with ATTR-CM ...
Pfizer Announces New Chief Scientific Officer and President, …
NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) today announced that after a comprehensive internal and external selection process, the company is appointing Chris Boshoff, M.D., PhD, as Chief Scientific Officer and President, Research & Development effective January 1, 2025. Dr. Boshoff, who most recently served as Chief Oncology Officer and Executive Vice President, will succeed Dr ...
Pfizer Announces New Chief Scientific Officer and President, …
6 days ago · NEW YORK, November 20, 2024--Pfizer Inc. (NYSE: PFE) today announced that after a comprehensive internal and external selection process, the company is appointing Chris Boshoff, M.D., PhD, as ...
European Commission Approves Pfizer’s HYMPAVZI™ …
Nov 20, 2024 · NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) announced today that the European Commission (EC) has granted marketing authorization for HYMPAVZI™ (marstacimab) for the routine prophylaxis of bleeding episodes in patients 12 years of age and older weighing at least 35 kg with severe hemophilia A (congenital factor VIII [FVIII] deficiency, FVIII <1%) without FVIII inhibitors or severe ...
Press Releases - Pfizer
U.S. FDA Approves Pfizer’s HYMPAVZI™ (marstacimab-hncq) for the Treatment of Adults and Adolescents with Hemophilia A or B Without Inhibitors
Pfizer lifts profit view on cost cuts, demand for COVID products
May 1, 2024 · Pfizer lifted its annual earnings forecast on Wednesday and reported a first-quarter profit above Wall Street estimates, boosted by cost cutting efforts and stronger-than-expected sales of its...
Pfizer rolls out another cost-cutting program, sets $1.5 billion …
May 22, 2024 · U.S. drugmaker Pfizer on Wednesday launched a new multi-year program to reduce its expenses by about $1.5 billion by the end of 2027, adding on to a $4 billion cost cutting plan it announced last...
Pfizer lifts profit forecast as investors await turnaround
Jul 30, 2024 · Pfizer raised its annual profit forecast on Tuesday, helped by cancer treatments acquired through a $43 billion deal for Seagen and strong sales of its heart disease drug as the company deals...
Stories & News - Pfizer Investor Insights
Stories & News. View More. View More. Join Pfizer Investor Insights. Sign up to receive important updates about Pfizer, how we’re innovating for patients and delivering value for shareholders. Email updates will also provide exciting opportunities for individual shareholders to hear from our leadership and experts.